# US 10,945,980 B2 · Treatment for myopia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,945,980 B2
- Document ID: US10945980B2
- Status: Granted
- Kind: B2
- Application number: 16/310,587
- Filed: 2017-06-21
- Published: 2019-05-16
- Granted: 2021-03-16
- Earliest claimed: 2016-06-21
- Assignees: The University of Newcastle
- Applicants: The University of Newcastle
- Inventors: Sally Anne McFadden
- Web page: https://patentgrep.com/patent/US10945980B2

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61P 27/02: Ophthalmic agents
- A61P 27/10: for accommodation disorders, e.g. myopia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are methods for treating or preventing myopia, or for inhibiting the development of myopia, comprising administering to a subject in need thereof an effective amount of an agent capable of increasing nitric oxide levels in one or more ocular cells or an agent capable of promoting or increasing the expression and/or activity of nNOS in one or more ocular cells. Also provided are methods for inducing or promoting nNOS expression and/or activity in one or more ocular cells, comprising exposing said cells to an effective amount of L-arginine.

## Claims

### Claim 1

A method for treating or preventing myopia, or for inhibiting the development of myopia, the method comprising administering to a subject in need thereof an effective amount of an agent that induces or promotes the expression and/or activity of neuronal nitric oxide synthase (nNOS) in one or more ocular cells thereby treating or preventing myopia or inhibiting the development of myopia.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the ocular cells express nNOS or are part of an nNOS producing structure in the eye.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the ocular cells are amacrine cells.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the agent that induces or promotes the expression and/or activity of nNOS in amacrine cells is L-arginine.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the agent is administered directly to an eye of the subject, or is administered orally or topically.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the administration is via intravitreal, conjunctival or scleral injection or an intravitreal, conjunctival or scleral implant.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the myopia is lens- or instrument-induced myopia, simple myopia, early or late-onset myopia, progressive myopia, degenerative myopia or pathological myopia.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the treatment, prevention or inhibition of development of myopia comprises inhibiting or preventing the progression of myopia in a myopic eye, reversing established myopia, or inhibiting or preventing the development of myopia in an eye predisposed thereto or at risk of developing myopia.